Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models
Molecular Pharmaceutics · 07.04.2025 · 22 (4) · 2131-2141
DOI: 10.1021/acs.molpharmaceut.4c01324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.03.2025. Verfasst von Wenting Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, Nebraska 68…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Neurotensin, Radiopharmaceuticals, Radioisotopes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Neurotensin receptor subtype 1 (NTSR1) is overexpressed in numerous cancers. Our laboratory is exploring the utilization of covalent cysteine protease inhibitors (e.g., E-64) to increase tumor retention of targeted radionuclide therapeutics (TRTs) through protein adduct formation. Using this approach, we reported [177Lu]Lu-NA-ET1, an NTSR1-targeted construct. In this work, we continue the exploration of [177Lu]Lu-NA-ET1 in three different NTSR1-positive cancer models. [177Lu]Lu-3BP-227, a clinically investigated NTSR1-targeted construct, was utilized as a comparative benchmark. Both [177Lu]Lu-NA-ET1 and [177Lu]Lu-3BP-227 underwent in vitro investigation, including internalization and autoradiographic sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) studies, in NTSR1-positive AsPC-1, HT-29, and PC-3 cell lines. Biodistribution, human radiation dosimetry, and in vivo autoradiographic SDS-PAGE studies were performed by using the same models. A dose escalation study using 585 MBq (15.8 mCi) of [177Lu]Lu-NA-ET1 was implemented in immunocompetent CF-1 mice. In all three cell lines, [177Lu]Lu-NA-ET1 demonstrated similar cellular uptake profiles relative to those of [177Lu]Lu-3BP-227. Biodistribution studies of [177Lu]Lu-NA-ET1 revealed increased (1.9-4.4-fold) tumor retention and radiation dose delivery relative to the control. Analysis of the in vitro and in vivo cellular and tissue lysates showed protein adducts that ranged from approximately 25-35 kDa, consistent with cysteine cathepsins, the speculative protein binding partner. A total of 585 MBq (15.8 mCi) of [177Lu]Lu-NA-ET1 was administered and found to be well-tolerated. Incorporating the covalent inhibitor in [177Lu]Lu-NA-ET1 resulted in an improved retention and radiation dose delivery profile compared to [177Lu]Lu-3BP-227. Examination of the therapeutic potential of [177Lu]Lu-NA-ET1 and further exploration of the chemical biology of this approach is underway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
- Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, 985830 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
- Department of Radiation Oncology, College of Medicine, University of Nebraska Medical Center, 985870 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
- Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, 984375 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
- Department of Pathology, Microbiology and Immunology, College of Medicine, University of Nebraska Medical Center, 985900 Nebraska Medical Center, Omaha, Nebraska 68198, United States.
ORCID-Profile: Maneesh Jain, Jered C Garrison
Förderung
- National Cancer Institute
Zitieren
APA
Zhang, W., Fan, W., Brake, K., Basiri, A., Hyun, M. A., Smith, L. M., Lele, S. M., Aithal, A., Jain, M., & Garrison, J. C. (2025). Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models. Molecular Pharmaceutics, 22(4), 2131-2141. https://doi.org/10.1021/acs.molpharmaceut.4c01324
Vancouver
Zhang W, Fan W, Brake K, Basiri A, Hyun MA, Smith LM, et al. Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models. Molecular Pharmaceutics. 2025;22(4):2131-2141. doi:10.1021/acs.molpharmaceut.4c01324
BibTeX
@article{Zhang2025,
author = {Zhang, Wenting and Fan, Wei and Brake, Katie and Basiri, Alireza and Hyun, Megan A and Smith, Lynette M and Lele, Subodh M and Aithal, Abhijit and Jain, Maneesh and Garrison, Jered C},
title = {Enhanced Retention of NTSR1-Targeted Radionuclide Therapeutics via Covalent Inhibitors in Pancreatic, Colorectal, and Prostate Cancer Models},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {4},
pages = {2131--2141},
doi = {10.1021/acs.molpharmaceut.4c01324}
}
EUVIMED